Director-Affiliated Fund Sells $7.4M in Opus Genetics Stock

summarizeSummary

A director-affiliated institutional fund sold $7.395 million worth of Opus Genetics common stock in an open market transaction, representing a significant reduction in its holdings.

check_boxKey Events

• Significant Insider Sale

  Foundation Fighting Blindness Retinal Degeneration Fund, an entity with director representation, sold 1,700,000 shares of common stock for $7,395,000.

• Large Stake Reduction

  This sale represents approximately 2.05% of the company's market capitalization and reduces the fund's direct holdings to 3,792,171 shares.

• Follows Recent Financing & Losses

  The sale occurs after Opus Genetics reported a substantial Q1 2026 net loss and secured new financing packages, including a $35 million tranche in April.

auto_awesomeAnalysis

Foundation Fighting Blindness Retinal Degeneration Fund, an institutional investor with director representation on the board, sold 1.7 million shares for $7.395 million. This significant sale, representing over 2% of the company's market capitalization, could be interpreted as a reduction in conviction by a major institutional holder. This follows a period of significant financing activities and a substantial Q1 net loss reported by Opus Genetics.